Department of Neurological Surgery, Nippon Medical School, Tokyo 113-8603, Japan; Department of Neurosurgery, Juntendo University Graduate School of Medicine, Tokyo 113-8431, Japan.
Department of Neurological Surgery, Nippon Medical School, Tokyo 113-8603, Japan.
Growth Horm IGF Res. 2023 Aug;71:101545. doi: 10.1016/j.ghir.2023.101545. Epub 2023 Jun 2.
The growth hormone (GH)-releasing peptide-2 (GHRP-2) test is relatively safe among endocrine stimulation tests for the elderly. We investigated whether anterior pituitary function in elderly patients could be assessed on the basis of GH response to the GHRP-2 test.
Sixty-five elderly patients aged 65 years and older with non-functioning pituitary neuroendocrine tumor (PitNET) who underwent pituitary surgery and preoperative endocrine stimulation tests were classified into the "GH normal group" and "GH deficiency group" based on GH response to the GHRP-2 test. The baseline characteristics and anterior pituitary function were compared between the groups.
Thirty-two patients were assigned to the GH normal group and 33 to the GH deficiency group. The cortisol and adrenocorticotropic hormone (ACTH) results in the corticotropin-releasing hormone test were significantly higher in the GH normal group than in the GH deficiency group (p < 0.001). The relationship between the cortisol and ACTH results and the GH response revealed significant correlations (p < 0.001). In addition, receiver operating characteristic curve analysis identified that the optimal cut-off point for a peak GH level in the correlation between adrenocortical function and GH response to the GHRP-2 test was 8.08 ng/mL (specificity 0.868, sensitivity 0.852).
The present study indicated that adrenocortical function was significantly correlated with GH response to the GHRP-2 test in elderly patients before pituitary surgery. For elderly patients with non-functioning PitNET, GH response to the GHRP-2 test may support in diagnosing adrenocortical insufficiency.
在用于老年人的内分泌刺激试验中,生长激素释放肽-2(GHRP-2)试验相对安全。我们研究了基于 GHRP-2 试验对 GH 反应,是否可以评估老年患者的垂体前叶功能。
65 名年龄在 65 岁及以上的无功能垂体神经内分泌肿瘤(PitNET)老年患者接受了垂体手术和术前内分泌刺激试验,根据 GHRP-2 试验对 GH 的反应,将其分为“GH 正常组”和“GH 缺乏组”。比较两组患者的基线特征和垂体前叶功能。
32 例患者被分配到 GH 正常组,33 例患者被分配到 GH 缺乏组。促肾上腺皮质激素释放激素试验中皮质醇和促肾上腺皮质激素(ACTH)结果在 GH 正常组显著高于 GH 缺乏组(p<0.001)。皮质醇和 ACTH 结果与 GH 反应之间的关系显示出显著相关性(p<0.001)。此外,受试者工作特征曲线分析确定,在 GHRP-2 试验中,肾上腺皮质功能与 GH 反应之间的 GH 峰值的最佳截断点为 8.08ng/mL(特异性 0.868,敏感性 0.852)。
本研究表明,在垂体手术前的老年患者中,肾上腺皮质功能与 GHRP-2 试验对 GH 的反应显著相关。对于无功能 PitNET 的老年患者,GHRP-2 试验对 GH 的反应可能有助于诊断肾上腺皮质功能不全。